NCT03561701View on ClinicalTrials.gov

A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

PHASE3CompletedINTERVENTIONAL
Enrollment

425

Participants

Timeline

Start Date

August 23, 2018

Primary Completion Date

October 13, 2020

Study Completion Date

August 3, 2021

Conditions
Recurrent Vulvovaginal Candidiasis
Interventions
DRUG

Oteseconazole (VT-1161)

Oteseconazole (VT-1161) 150mg capsule

DRUG

Placebo

matching placebo capsule

Trial Locations (14)

21740

31245, Hagerstown

27103

31223, Winston-Salem

33030

31204, Homestead

33141

31233, North Bay Village

38305

31218, Jackson

43213

31244, Columbus

43231

31229, Columbus

45322

31222, Englewood

67226

31255, Wichita

72212

31227, Little Rock

75035

31232, Frisco

85032

31215, Phoenix

90057

31217, Los Angeles

06105

31240, Hartford

Sponsors
All Listed Sponsors
lead

Mycovia Pharmaceuticals Inc.

INDUSTRY